These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 35893744)

  • 1. Matrix Metalloproteinase 2 as a Pharmacological Target in Heart Failure.
    Gonçalves PR; Nascimento LD; Gerlach RF; Rodrigues KE; Prado AF
    Pharmaceuticals (Basel); 2022 Jul; 15(8):. PubMed ID: 35893744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MMP-2 and TIMP-2 in Patients with Heart Failure and Chronic Kidney Disease.
    Kobusiak-Prokopowicz M; Krzysztofik J; Kaaz K; Jolda-Mydlowska B; Mysiak A
    Open Med (Wars); 2018; 13():237-246. PubMed ID: 29915813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Extracellular Matrix Remodeling during Left Ventricular Diastolic Dysfunction and Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.
    Krebber MM; van Dijk CGM; Vernooij RWM; Brandt MM; Emter CA; Rau CD; Fledderus JO; Duncker DJ; Verhaar MC; Cheng C; Joles JA
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32937927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterizing heart failure with preserved and reduced ejection fraction: An imaging and plasma biomarker approach.
    Kanagala P; Arnold JR; Singh A; Chan DCS; Cheng ASH; Khan JN; Gulsin GS; Yang J; Zhao L; Gupta P; Squire IB; Ng LL; McCann GP
    PLoS One; 2020; 15(4):e0232280. PubMed ID: 32349122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of matrix metalloproteinases (MMPs) as a potential strategy to ameliorate hypertension-induced cardiovascular alterations.
    Castro MM; Tanus-Santos JE
    Curr Drug Targets; 2013 Mar; 14(3):335-43. PubMed ID: 23316965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
    Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR
    Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential expression of MMPs and TIMPs in moderate and severe heart failure in a transgenic model.
    Mori S; Gibson G; McTiernan CF
    J Card Fail; 2006 May; 12(4):314-25. PubMed ID: 16679266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation.
    Paulus WJ; Tschöpe C
    J Am Coll Cardiol; 2013 Jul; 62(4):263-71. PubMed ID: 23684677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between serum matrix metalloproteinase and myocardial fibrosis in heart failure patients with reduced ejection fraction: A retrospective analysis.
    Çelik Ö; Şahin AA; Sarıkaya S; Uygur B
    Anatol J Cardiol; 2020 Nov; 24(5):303-308. PubMed ID: 33122477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renin-Angiotensin System Inhibition, Worsening Renal Function, and Outcome in Heart Failure Patients With Reduced and Preserved Ejection Fraction: A Meta-Analysis of Published Study Data.
    Beldhuis IE; Streng KW; Ter Maaten JM; Voors AA; van der Meer P; Rossignol P; McMurray JJ; Damman K
    Circ Heart Fail; 2017 Feb; 10(2):. PubMed ID: 28209765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiac diastolic and autonomic dysfunction are aggravated by central chemoreflex activation in heart failure with preserved ejection fraction rats.
    Toledo C; Andrade DC; Lucero C; Arce-Alvarez A; Díaz HS; Aliaga V; Schultz HD; Marcus NJ; Manríquez M; Faúndez M; Del Rio R
    J Physiol; 2017 Apr; 595(8):2479-2495. PubMed ID: 28181258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Remote Hind-Limb Ischemia Mechanism of Preserved Ejection Fraction During Heart Failure.
    Homme RP; Zheng Y; Smolenkova I; Singh M; Tyagi SC
    Front Physiol; 2021; 12():745328. PubMed ID: 34858202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sympathetic and renin-angiotensin-aldosterone system activation in heart failure with preserved, mid-range and reduced ejection fraction.
    Vergaro G; Aimo A; Prontera C; Ghionzoli N; Arzilli C; Zyw L; Taddei C; Gabutti A; Poletti R; Giannoni A; Mammini C; Spini V; Passino C; Emdin M
    Int J Cardiol; 2019 Dec; 296():91-97. PubMed ID: 31443984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarker Profiles in Heart Failure Patients With Preserved and Reduced Ejection Fraction.
    Tromp J; Khan MA; Klip IT; Meyer S; de Boer RA; Jaarsma T; Hillege H; van Veldhuisen DJ; van der Meer P; Voors AA
    J Am Heart Assoc; 2017 Mar; 6(4):. PubMed ID: 28360225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drugs That Ameliorate Epicardial Adipose Tissue Inflammation May Have Discordant Effects in Heart Failure With a Preserved Ejection Fraction as Compared With a Reduced Ejection Fraction.
    Packer M
    J Card Fail; 2019 Dec; 25(12):986-1003. PubMed ID: 31541742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationships between plasma levels of matrix metalloproteinases and neurohormonal profile in patients with heart failure.
    Yan AT; Yan RT; Spinale FG; Afzal R; Gunasinghe HR; Stroud RE; McKelvie RS; Liu PP
    Eur J Heart Fail; 2008 Feb; 10(2):125-8. PubMed ID: 18234554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma matrix metalloproteinase-9 level is correlated with left ventricular volumes and ejection fraction in patients with heart failure.
    Yan AT; Yan RT; Spinale FG; Afzal R; Gunasinghe HR; Arnold M; Demers C; McKelvie RS; Liu PP
    J Card Fail; 2006 Sep; 12(7):514-9. PubMed ID: 16952784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Left atrial volume and left ventricular mass indices in heart failure with preserved and reduced ejection fraction.
    Gehlken C; Screever EM; Suthahar N; van der Meer P; Westenbrink BD; Coster JE; Van Veldhuisen DJ; de Boer RA; Meijers WC
    ESC Heart Fail; 2021 Aug; 8(4):2458-2466. PubMed ID: 34085774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction.
    Bishu K; Deswal A; Chen HH; LeWinter MM; Lewis GD; Semigran MJ; Borlaug BA; McNulty S; Hernandez AF; Braunwald E; Redfield MM
    Am Heart J; 2012 Nov; 164(5):763-770.e3. PubMed ID: 23137508
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.